natgillin/translations-raw huggingface dataset:
The freeze-dried formulation of claim 1 consisting of recombinant human follicle-stimulating hormone, recombinant human luteinising hormone, polyoxyethylene (20) sorbitan monolaurate, sucrose, methionine, and a phosphate-buffer. 
Smrzavanjem osušena formulacija prema bilo kojem od prethodnih zahtjeva, naznačena time da se sastoji od slijedećih sastojaka: rFSH, rLH, Tween 20, sukroze, metionina, fosfatnog pufera,
The integrated circuit according to claim 13, wherein, the transmission circuitry, in operation, controls transmission of higher layer control information indicating use of the transmission power value of the A-SRS based pm the second accumulation value. 
Postupak radio komunikacije sukladno zahtjevu 5, sadržeći primanje kontrolne informacije višeg sloja, naznačeno time da se navedeno upravljanje vrijednosti snage prijenosa A-SRS-a inicira nakon navedenog primanja kontrolne informacije višeg sloja.
In an embodiment, the pharmaceutical composition has a pH in the range of 5.5 to 7.0. In an embodiment the frequency of an immediate post injection reaction or the frequency of an injection site reaction is reduced relative to daily subcutaneous administration of 20 mg glatiramer acetate. 
Lijek za uporabu prema patentnom zahtjevu 1 ili glatiramer acetat za uporabu prema patentnom zahtjevu 2, naznačeni time, da je učestalost reakcije neposredno nakon injekcije ili reakcije na mjestu uboda smanjena u odnosu na učestalost pretrpljenu uz dnevno supkutano davanje od 20 mg glatiramer acetata.
A combination according to claim 1 or 2, wherein the B2 agonist is selected from the group comprising arformoterol, bambuterol, bitolterol, broxaterol, carbuterol, clenbuterol, dopexamine, fenoterol, hexoprenaline, ibuterol, isoprenaline, levosalbutamol, mabuterol, meluadrine, nolomirole, orciprenaline, pirbuterol, procaterol, (R,R)-formoterol, reproterol, ritodrine, rimoterol, salbutamol, sibenadet, sulfonterol, terbutaline and tulobuterol, optionally in the form of their racemates, their enantiomers, their diastereomers and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts. 
Kombinacija prema zahtjevu 1 ili 2, naznačena time, da je B2 agonist odabran iz skupine koja sadrži arformoterol, bambuterol, bitolterol, broksaterol, karbuterol, klenbuterol, dopeksamin, fenoterol, heksoprenalin, ibuterol, izoprenalin, levosalbutamol, mabuterol, meluadrin, nolomirol, orciprenalin, pirbuterol, prokaterol, (R,R)-formoterol, reproterol, ritodrin, rimoterol, salbutamol, sibenadet, sulfonterol, terbutalin i tulobuterol, po izboru u obliku njihovih racemata, njihovih enantiomera, njihovih diastereomera i njihovih smjesa, te prema potrebi njihovih farmakološki kompatibilnih kiselinskih adicijskih soli.
The vector of paragraph 34, wherein the CD3 zeta signaling domain is encoded by the nucleic acid sequence of SEQ ID NO: 18. A method for stimulating a T cell-mediated immune response to a target cell population or tissue in a mammal, the method comprising administering to a mammal an effective amount of a cell genetically modified to express a CAR wherein the CAR comprises an antigen binding domain, a costimulatory signaling region, and a CD3 zeta signaling domain comprising the amino acid sequence of SEQ ID NO: 24, wherein the antigen binding domain is selected to specifically recognize the target cell population or tissue. 
HR P20182202 T1 PATENTNI ZAHTJEVI no T stanica koja je genetski modificirana tako da eksprimira CAR, naznačena time što CAR sadrži (a) antigen vezujuću domenu koja je anti-CD19 scFv, (b) kostimulatorno signalno područje 4-1BB, i (c) signalnu domenu CD3 zeta za upotrebu u postupku za liječenje raka kod čovjeka, pri čemu anti-CD19 scFv sadrži aminokiselinsku sekvencu prema SEQ ID NO:20 i/ili signalnu domenu CD3 zeta sadrži aminokiselinsku sekvencu prema SEQ ID NO:24, 1 pri čemu je čovjek otporan na liječenje najmanje jednim kemoterapijskim sredstvom.
2 a . Another variation of said front wall 8, featuring extrusion ridge 17 alongside line 18, is disclosed in FIG. 
Druga varijanta navedenog prednjeg zida 8 s udubljenim rubom 17 paralelno liniji 18, otkrivena je u SI. 1b, dok je njena shema prikazan u Sl. 2b.
The antibody or antigen-binding fragment thereof according to claims 1 or 2, wherein the antibody or antigen-binding fragment is selected from the group consisting of a monoclonal antibody, a Fab fragment, an Fab' fragment, an F(ab')2 fragment, an Fv fragment, a diabody, and a single chain antibody. 
Monoklonsko protutijelo ili njegov antigen-vezujući fragment prema patentnom zahtjevu 1, naznačeno time što monoklonsko protutijelo ili njegov antigen-vezujući fragment selektivno inhibira ljudski CGRP receptor u usporedbi s ljudskim AM1, AM2, i AMY1 receptorima s omjerom selektivnosti od 100 ili više kao što je određeno s testom inhibicije cAMP.
Process according to claim 12, further comprising the step of laminating a transparent foil over said magnetically induced image coating. 
Postupak prema zahtjevu 11, naznačen time da dodatno sadrži korak laminiranja transparentne folije preko navedenog magnetski induciranog slikovnog premaza.
The bicomponent fiber of claim 1, wherein the bicomponent fiber comprises from 75% to 98% of the first polymer component and from 2% to 25% of the second polymer component, by weight of the bicomponent fiber. 
polaganje vlakana na sakupljačku površinu u svrhu stvaranja trake koja obuhvaća oba navedena polimerna sastojka, naime i prvi polimerni sastojak i drugi polimerni sastojak;
Control stage 3a, 3b comprises a one-input, four-output demultiplexer circuit 12a, 12b, which receives the signal generated by respective microprocessor 6a, 6b, and in turn generates four output signals OUT1a/b, OUT2a/b, OUT3a/b, OUT4a/b, each for controlling a respective beacon; and a comparing circuit 14a, 14b for receiving and comparing, bit by bit, the corresponding signals generated by first and second circuit section 1a, 1b. 
Upravljački podsklop 3a, 3b sadrži jednoulazni, četveroizlazni demultipleksni komunikacijski krug 12a, 12b, koji prima signal generiran odnosnim mikroprocesorom 6a, 6b i po redu generira četiri izlazna signala OUTI1a/b, OUT2a/b, OUT3a/b, OUT44/b, od kojih je svaki za upravljanje odnosnom batizom; i uspoređujući komunikacijski krug 14a, 14b za primanje i bit-po-bit usporedbu, odgovarajućih signala gencriranih prvom i drugom sekcijom komunikacijskih krugova la, 1b.
A use of an efflux protein inhibitor for the manufacture of a medicament to improve the bioavailability of a renin inhibitor, or a pharmaceutically acceptable salt thereof. 
Uporaba inhibitora istjecanja proteina u poboljšanju bioraspoloživosti inhibitora renina ili njegove farmaceutski prihvatljive soli, naznačena time, da inhibitor istjecanja proteina je PSC833.
Dry mortar blend comprising at least a binder, an aggregate and a setting accelerator, wherein the setting accelerator is a powder comprising calcium nitrate and having a water content between 0.1% by weight and 20% by weight and a particle size of 0.1 mm to 1 mm. 
Smjesa suhog morta, naznačena time, da sadržava barem vezivo, agregat i akcelerator vezivanja, pri čemu je akcelerator vezivanja prašak koji sadržava kalcijev nitrat i ima udjel vode između 0,1 % 1 20 % 1 veličinu čestica od 0,1 mm do 1 mm.
substituted and unsubstituted heterocyclyl. 
(b) supstituirani i nesupstituirani heterociklil.
Another object of the invention is an antibody whose sequence comprises the polypeptide sequences SEQ ID NO: 2 and 22. 
teški lanac koji sadrži polipeptidnu sekvencu SEQ ID NO: 2 i laki lanac koji sadrži polipeptidnu sekvencu SEQ ID NO: 22, ili -
R1d and R1e are independently a hydrogen atom, a halogen atom, a cyano group, a hydroxyl group, a C1-6alkyl group or a hydroxyl-C1-6alkyl group, or together form a C1-6alkylene group wherein one or two or more methylene groups constituting the alkylene group may be independently replaced by an oxygen atom, a sulfur atom, a sulfinyl group, a sulfonyl group, a carbonyl group, a vinylene group or a group of -N(R1f)-, and/or substituted by a hydroxyl group or a C1-6alkyl group; 
d i R1e su nezavisno atom vodika, halogen atom, cijano skupina, hidroksil skupina, niža alkilna skupina ili hidroksi-niža alkilna skupina, ili zajedno formiraju nižu alkilen skupina gdje jedna ili više metilenskih skupina koje čine nižu alkilen skupinu mogu nezavisno biti zamijenjene atomom kisika, atomom sumpora, sulfinil skupinom, sulfonilom skupinom, karbonil skupinom, vinilen skupinom ili skupinom -N(R1f)-, i/ili supstituirane hidroksil skupinom ili nižom alkilnom skupinom;
Accordingly, in a further aspect the invention relates to a compound of formula I for use as a medicament. 
Prema tome, u daljnjem aspektu ovaj se izum odnosi na spoj formule I za primjenu kao lijek.
A pharmaceutical product for use according claim 4, wherein said active ingredient is the human B2-microglobulin protein. 
Farmaceutski sastav u skladu s patentnim zahtjevom 4, pri čemu je navedeni aktivni sastojak ljudski protein B2-mikroglobulin.
The compound of claim 1 where X is cyclopentyl, cyclohexyl, thienyl, furyl, pyridinyl, or optionally substituted phenyl. 
Spoj iz zahtjeva 3, naznačen time, da Y je ciklopentil, cikloheksil, tienil, furil, piridinil, ili po izboru supstituirani fenil.
Use according to embodiment 2 to 4, characterised in that not more than six top-up doses of CNS 7056 are given. 
CNS 7056 ili njegova sol ili solvat za primjenu sukladno zahtjevu 2 do 4, naznačen time što se ne daje više od šest dopunskih doza CNS 7056.
Formulations for topical administration may take the form of creams, ointments, gels or transdermal delivery systems, e.g., patches. 
Formulacije za površinsko davanje mogu imati oblik kreme, pomasti, gela ili sistema za transdermalnu isporuku, npr. flastera.
FIGURE 12 is a view similar to Figure 6 of the second container embodiment showing a further assembly step. 
SLIKA 12 je pogled na spremnik sličan onome iz slike 6, koja slika prikazuje daljnji korak sklapanja druge izvedbe spremnika.
treating a hypophosphatemia disorder, wherein said hypophosphatemia disorder is X-linked hypophosphatemic rickets, autosomal recessive hypophosphatemic rickets, and autosomal dominant hypophosphatemic rickets, or tumor-induced osteromalacia. 
liječenju poremećaja, pri čemu navedeni poremećaj hipofosfatemije je X-vezani hipofosfatemični rahitis, autosomni recesivni hipofosfatemični rahitis, i autosomni dominantni hipofosfatemični rahitis, ili osteomalacija izazvana tumorom.
The method of claim 1, wherein the {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid or a pharmaceutically acceptable salt thereof and the metformin are administered in separate dosage forms. 
Sol koja sadrži jedan molekularni kation i jedan molekularni anion, naznačena time što je molekularni kation kation od 1,1-dimetilbiguanida i molekularni anion je anion aktivatora glukokinaze, pri čemu je aktivator glukokinaze {2-[3-cikloheksil-3-(trans-4-propoksi-cikloheksil)-ureido]-tiazol-5-ilsulfanil}-octena kiselina.
The antibody, immunoconjugate, bispecific or multispecific molecule, pharmaceutical composition or expression vector for use according to any one of claims 21 to 23, wherein said use comprises administration of one or more further therapeutic agents to the subject. 
Antitijelo, imunokonjugat, bispecifična ili multispecifična molekula, farmaceutski pripravak ili vektor ekspresije za primjenu prema bilo kojem zahtjevu od 18 do 21, naznačen time, što se postupak sastoji od primjene jednog ili više dodatnih terapeutskih sredstava kod bolesnika.
2 from nucleotide 1452 to nucleotide 1843 or the nucleotide sequence of SEQ ID No 3 from nucleotide 1 to nucleotide 240 or the nucleotide sequence of SEQ ID No 1 from nucleotide 188 to nucleotide 7252 or its complement, and wherein said primer recognizing the 5' flanking region of EE-GM2 comprises at its extreme 3' end a nucleotide sequence of at least 17 consecutive nucleotides selected from the nucleotide sequence of SEQ ID No 14 from nucleotide 1 to nucleotide 311 or said primer recognizing the 3' flanking region of EE-GM2 comprises at its extreme 3' end a nucleotide sequence of at least 17 consecutive nucleotides selected from the nucleotide sequence of the complement of SEQ ID No 15 from nucleotide 508 to nucleotide 1880, and said primer recognizing a sequence within the foreign DNA of EE-GM2 comprises at its 3' end at least 17 consecutive nucleotides selected from the nucleotide sequence of the complement of SEQ ID No. 
2 od nukleotida 1452 do nukleotida 1843 ili nukleotidnu sekvencu iz SEQ ID No 3 od nukleotida 1 do nukleotida 240 ili nukleotidnu sekvencu iz SEQ ID No 1 od nukleotida 188 do nukleotida 7252 ili njezin komplement, te pri čemu navedena početnica koja prepoznaje 5' bočnu regiju od EE-GM2 sadrži na njenom krajnjem 3' završetku nukleotidnu sekvencu od barem 17 uzastopnih nukleotida odabranih iz nukleotidne sekvence iz SEQ ID No 14 od nukleotida 1 do nukleotida 311 ili navedena početnica koja prepoznaje 3' bočnu regiju od EE-GM2 sadrži na njenom krajnjem 3' završetku nukleotidnu sekvencu od barem 17 uzastopnih nukleotida odabranih iz nukleotidne sekvence iz komplementa od SEQ ID No 15 od nukleotida 508 do nukleotida 1880, te navedena početnica koja prepoznaje sekvencu unutar strane DNA od EE-GM2 sadrži na njenom 3' završetku barem 17 uzastopnih nukleotida odabranih iz nukleotidne sekvence iz komplementa od SEQ ID No.
The cocrystalline form according to claim 11 characterized by an X-ray powder diffraction pattern using CuKa radiation having a diffraction peak at diffraction angle 2-theta of 7.0° in combination with one or more of the peaks selected from the group consisting of 18.8°, 16.1°, and 19.3°; with a tolerance for the diffraction angles of 0.2 degrees. 
Sukristalni oblik u skladu s patentnim zahtjevom 11, naznačen time što ima uzorak difrakcije rendgenskih zraka na prahu, uz upotrebu CuK., zračenja, s difrakcijskim maksimumom pod difrakcijskim kutom 26 od 7,0", u kombinaciji s jednim ili više maksimuma koje se bira iz skupine koju čine 18,8%, 16,1", te 19.3% uz toleranciju za difrakcijske kutove od 0,2%.
The method according to claim 1, wherein at least 30% of the polysaccharide chains have a molecular weight of at least 8 kDa. 
Kemijski modificiran heparin prema zahtjevima 1 ili 2, naznačen time da najmanje 30% polisaharidnih lanaca ima molekularnu masu od najmanje $ kDa.
The method according to claim 3, wherein the planar wooden core is formed by cross-laminated timber. 
Postupak sukladno zahtjevu 3, pri čemu je planarna drvena jezgra (41, 46) formirana poprečno laminiranim drvetom.
Method for providing information to a user from a capsule for the preparation of a beverage using a code 
POSTUPAK DAVANJA INFORMACIJA KORISNIKU IZ KAPSULE ZA PRIPRAVU NAPITKA, UZ UPOTREBU KODA
Process according to any one of claims 1 to 15, characterized in that the aqueous solution comprising at least one earth alkali hydrogen carbonate that is obtained in step e) or step f) has a turbidity value of lower than 1.0 NTU, preferably of lower than 0.5 NTU, and most preferably of lower than 0.3 NTU. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time da vodena otopina koja sadrži barem jedan zemnoalkalijski hidrogenkarbonat koja se dobiva u koraku e) ima vrijednost zamućenosti nižu od 0.5 NTU, te poželjno nižu od 0.3 NTU.
a heavy chain having at least 90% sequence identity to the amino acid sequence of SEQ ID NO:88, or/and 
sekvencu jakog lanca odabranu od bilo koje od SEQ ID NO:88 ili SEQ ID NO:92;
A molecule comprising a saccharide moiety of formula: wherein 
Molekula koja sadrži saharidni ostatak formule:
a boost capacitor device comprising at least one boost capacitor; 
uređaj sa kondenzatorskim pojačalom koji sadrži barem jedno kondenzatorsko pojačalo.
is -H or methyl; and M+ is a pharmaceutically acceptable monovalent cation and M2+ is a pharmaceutically acceptable divalent cation. 
je -II ili metil; i M+ je farmaceutski prihvatljiv jedno valentni kation i M2+ je farmaceutski prihvatljiv dvovalentni kation.
A recombinant molecule or a set of at least two nucleic acid molecules according to any one of claims 4-6, wherein said molecule is or said at least two nucleic acid molecules are linear. 
Rekombinantna molekula ili skup od barem dvije molekule nukleinske kiseline prema bilo kojem zahtjevu od 4-6, naznačena time da je navedena molekula ili navedene barem dvije molekule nukleinske kiseline su linearne.
The compound according to claim 8, in the form of a salt with a pharmaceutically acceptable acid or base. 
Spoj u skladu s patentnim zahtjevom 5, naznačen time, da je u obliku soli s farmaceutski prihvatljivom kiselinom ili lužinom.
A further embodiment of the present invention relates to the treatment of a sleep disorder wherein the sleep disorder is a circadian rhythm sleep disorder. 
Upotreba spoja u skladu s patentnim zahtjevom 25, gdje poremećaj spavanja je poremećaj cirkadijanog ritma spavanja.
Thus, when n is 1, the R5 group is suitably at an ortho-(2-) or a meta-(3-) position on the benzene ring. 
Stoga, kada je n jednak 1, R* skupina je poželjno na orto-(2-) ili meta-(3-) položaju benzenskog prstena.
The remaining pellets on the sieve could be re dissolved again. 
Pelete preostale na situ se mogu ponovno otopiti.
wherein the immunoglobulin heavy chain of (a) and the immunoglobulin light chain of (b) form an anti-B7RP1 IgG antibody, comprising two molecules of the polypeptide of (a) and two molecules of the light chain of (b); wherein the protein binds to BAFF and inhibits BAFF-mediated proliferation of human B cells, and wherein the protein binds to B7RP1 and inhibits B7RP1-mediated proliferation of human T cells. 
laki lanac imunoglobulina IgG antitijela, naznačen time što teški lanac imunoglobulina iz (a) i laki lanac imunoglobulina iz (b) formiraju IgG antitijelo koje veže B7RP1, pri čemu protein sadrži dvije molekule polipeptida iz (a) i dvije molekule lakog lanca iz (b), pri čemu protein inhibira BAFF-posredovanu proliferaciju humanih B stanica, i pri čemu protein inhibira B7RP1-posredovanu proliferaciju humanih T stanica.
A process as claimed in claim 9 in which the heated liquid is heated to a temperature of the order of 85° C. 
Postupak prema zahtjevima 4 do 10 gdje se zagrijana tekućina zagrijava na temperaturu vrijednosti 85%C.
attaching an isosubstrate of the isoprenoid transferase to an active agent; and, enzymatically reacting, using the isoprenoid transferase, the expressed antibody with the active agent attached to the isosubstrate. 
(b) vezanje izosupstrata izoprenoid transferaze na aktivno sredstvo; i, (c) enzimska reakcija, koristeći izoprenoid transferazu, pri čemu se eksprimirano antitijelo s aktivnim sredstvom veže na izosupstrat.
The extended release dosage form of any one of claims 1 to 29, which is in the form of a tablet and which is over coated with a polyethylene oxide powder layer to form a tablet that has a core tablet and a layer of polyethylene oxide surrounding the core tablet. 
Oblik za doziranje s produljenim otpuštanjem prema bilo kojem zahtjevu od 1 do 23, naznačen time da je u obliku tablete, a koja je obložena slojem polietilen oksida u prahu tako da tvori tabletu koja ima jezgru tablete i sloj polietilen oksida koji obavija jezgru tablete.
The method of either of claims 1 or 2, further comprising identifying the subject is not at increased risk of developing PML when the level of JCV antibody in the pre-incubated biological sample binding to the immobilized HPVLPs is approximately the same as the level of JCV antibody detected in the biological sample obtained from the subject that was pre-incubated in a solution without HPVLPs. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što biološki uzorak dobiven iz subjekta se klasificira kao negativan na protutijelo protiv ICV kada je razina protutijela protiv ICV u predinkubiranom biološkom uzorku koja se vežu na imobilizirane HPVLP-e otprilike ista kao razina protutijela protiv JCV detektirana u biološkom uzorku dobivenom iz subjekta predinkubiranom u otopini bez HPVLP-a.
Example 4: Synthesis of the compounds 
Broj objave europskog patenta:
An anti-NogoA antibody, functional fragment or analogue thereof according to any one of claims 1 to 8, for use in a method of treatment of stroke, traumatic brain injury, spinal cord injury, Alzheimer's disease, fronto-temporal dementias (tauopathies), peripheral neuropathy, Parkinson's disease, Huntington's disease or multiple sclerosis in a human. 
Protutijelo protiv Nogo-A, ili njegov funkcionalni fragment ili analog, u skladu s bilo kojim od patentnih zahtjeva 1 do 8, namijenjeno upotrebi u postupku liječenja inzulta, traumatske ozljede mozga, ozljede kralježničke moždine, Alzheimerove bolesti, fronto-temporalnih demencija (tauopatija), periferne neuropatije, Parkinsonove bolesti, Huntingtonovo bolesti ili multiple skleroze kod čovjeka.
Cocoa-derived beverage according to claim 13 having an ORAC value of at least 1000 µmol TE/100 ml, preferably of at least 2000 µmol TE/100 ml, and most preferably having an ORAC value of between 2500 and 3500 µmol TE/100 ml. 
ORAC najmanje 1.000 Pmol TE/100 ml, poželjno je najmanje 2.000 Pmol TE/100 ml, a najpoželjnija je vrijednost prema ljestvici ORAC u rasponu od 2.500 do 3.500 Pmol TE/100 ml.
Process according to claim 4 characterized in that the compound obtained is enantiomerically pure (R)-pirlindole citrate salt. 
Proces u skladu sa patentnim zahtjevom 4 naznačen time da dobiveni spoj je enantiomerno čista (R)-pirlindol citrat sol.
Moreover, inactivation of A2A receptors has been shown to selectively attenuate amphetamine-induced behavioural sensitisation (Chen et al., 2003, Neuropsychopharmacol 28: 1086-1095). 
Čak štoviše, inaktivacija A2,-receptora pokazuje selektivno smanjivanje senzacija u ponašanju uzrokovanih amfetaminom (Chen et al., 2003, Neuropsychopharmacol 28: 1086-1095).
The third aluminum layer 13 provides the sheet with the ability to reflect light and infrared radiation, facilitating preservation of the freshness of the food contained in the package. 
Treći aluminijski sloj 13 podaje ploči sposobnost refleksije svjetla i infracrvenog zračenja, olakšavajući očuvanje svježine hrane koja se nalazi u pakovanju.
The salt of a compound of formula (I) according to claim 2 selected from an alkali or alkaline-earth metal, an organic amine or an amino acid. 
Sol spoja formule (I) prema patentnom zahtjevu 2 s alkalijskim ili zemnoalkalijskim metalom, organskim aminom ili aminokiselinom.
A cocktail of polypeptides comprising at least first and second different polypeptides wherein the first polypeptide is a polypeptide according to claim 1 or 2 and wherein the second polypeptide comprises a sequence selected from the group consisting of: SEQ. 
Koktel polipeptida koji sadrži barem dva različita polipeptida, gdje najmanje dva različita polipeptida sadrže koktel polipeptida odabran iz grupe koja se sastoji od: i) - koktela od: polipeptida koji sadrži sekvencu sa SEQ.
The animal of claim 1, wherein the animal does not express functional endogenous MHC I, II a, and II B polypeptides from the endogenous non-human MHC loci on a cell surface. 
Životinja prema zahtjevu 1, naznačena time, da životinja ne izražava funkcionalne endogene MHC-I-, II-a- i IIB-polipeptide iz endogenih ne-humanih MHC-loci na površinu stanice.
Preferably the tablet comprises lactose as diluent. 
Poželjno tableta sadržava laktozu kao razrjeđivač.
(Vlllb) reacting an intermediate of formula (XXI') with a suitable reducing agent and a suitable solvent, With R1, R2, R1a, and n as defined in claim 1; 
(Vlllb) reakcija intermedijera formule (XXI’) s prikladnim reducensom i prikladnim otapalom, [image] s R1, R2, R1a, i n kako su definirani u zahtjevu 1;
The compound or salt thereof can be used in combination with an anti-dyslipidaemia agent including but not limited to a statin, a fibrate, a niacin and/or a cholesterol absorption inhibitor. 
(d) sredstvo za liječenje dislipidemije je statin, fibrat, niacin i/ili inhibitor apsorpcije kolesterola.